565453-43-2

Upstream product

• 702-82-9 3-aminoadamantan-1-ol 
• 501-53-1 benzyl chloroformate 

Downstream Products

• 1026223-11-9 3-[[(cyclohexylamino)carbonyl]oxy]-1-aminoadamantane 
• 1027414-42-1 3-[[(4-methoxyphenylamino)carbonyl]oxy]-1-aminoadamantane 
• 1027175-44-5 3-[[(phenylamino)carbonyl]oxy]-1-aminoadamantane 
• 565453-44-3 (3-tert-butylcarbamoyloxy-adamantan-1-yl)-carbamic acid benzyl ester 
• 620170-84-5 [3-(4-methoxy-phenylcarbamoyloxy)-adamantan-1-yl]-carbamic acid benzyl ester 
• 620171-36-0 (3-phenylcarbamoyloxy-adamantan-1-yl)-carbamic acid benzyl ester 
• 620171-50-8 (3-diisopropylcarbamoyloxy-adamantan-1-yl)-carbamic acid benzyl ester 
• 620171-66-6 acetic acid 3-benzyloxycarbonylamino-adamantan-1-yl ester 
• 620171-62-2 (3-cyclohexylcarbamoyloxy-adamantan-1-yl)-carbamic acid benzyl ester 

Relevant academic research and scientific papers

Photoredox-catalyzed deoxyfluorination of activated alcohols with Selectfluor

Herein we disclose a deoxyfluorination of alcohols with an electrophilic fluorine source via visible-light photoredox catalysis. This radical-mediated C–F coupling is capable of fluorinating secondary and tertiary alcohols efficiently, complementing previously reported nucleophilic deoxyfluorination protocols.

Naphthoquinone derivative containing adamantyl and preparation method and application of derivative

The invention provides a naphthoquinone derivative containing adamantyl and a preparation method and application of the derivative, and particularly provides a naphthoquinone derivative which is as shown in a following formula (I) and contains adamantyl, wherein definitions of all groups are described in the description. The compound has Sortase A enzyme inhibitory activity and cytotoxic activity and can be used for treating diseases related to Sortase A enzyme and various malignant tumors. Please see the formula (I) in the description.

1-[[(3-Hydroxy-1-adamantyl)amino]acetyl]-2-cyano-(S)-pyrrolidine: A potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties

Dipeptidyl peptidase IV (DPP-IV) inhibition has the potential to become a valuable therapy for type 2 diabetes. The synthesis and structure - activity relationship of a new DPP-IV inhibitor class, N-substituted-glycyl-2-cyanopyrrolidines, are described as well as the path that led from clinical development compound 1-[2-[5-cyanopyridin-2-yl)amino]ethylamino]acetyl-2-cyano-(S)pyrrolidine (NVP-DPP728, 8c) to its follow-up, 1-[[(3-hydroxy-1-adamantyl)amino]acetyl]-2-cyano-(S)pyrrolidine (NVP-LAF237, 12j). The pharmacological profile of 12j in obese Zucker fa/fa rats along with pharmacokinetic profile comparison of 8c and 12j in normal cynomolgus monkeys is discussed. The results suggest that 12j is a potent, stable, selective DPP-IV inhibitor possessing excellent oral bioavailability and potent antihyperglycemic activity with potential for once-a-day administration.